Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia (PR-CS008)
Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
Sponsor: La Jolla Pharmaceutical Company
A PHASE2 clinical study on Chronic Lymphocytic Leukemia, this trial is completed. The trial is conducted by La Jolla Pharmaceutical Company and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- La Jolla Pharmaceutical Company
For direct contact, visit the study record on ClinicalTrials.gov .